New Long-Acting Analgesic Independently Developed by Kingpre Biotech, a Direct-Investee of Nanjing Venture Capital Group, Submitted for Market Approval
Recently, Kingpre Biotech, a direct-invested enterprise of Nanjing Venture Capital Group, announced a major milestone: the New Drug Application (NDA) for QP-6211, its independently developed long-acting analgesic, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The drug is intended for postoperative analgesia in adults. This landmark breakthrough not only demonstrates the company’s strong independent R&D capability but also provides a new clinical option for postoperative pain management.
QP-6211 is a non-opioid long-acting analgesic developed on Kingpre Biotech’s proprietary sustained-release injection platform. Compared with globally marketed products targeting the same receptor, it features three core advantages:
Longer duration: a single dose provides stable analgesia for 72 hours, greatly improving patients’ quality of life after surgery;
Better safety: significantly reduced cardiac and central nervous system toxicity, with controllable injection risks;
Higher pain nerve selectivity: precisely targets pain pathways to achieve highly effective analgesia.
Clinical data show that in procedures such as hemorrhoidectomy and unilateral hallux valgus correction, QP-6211 demonstrated significantly superior analgesic efficacy compared with the active control and placebo groups, with favorable overall safety, fully meeting the clinical requirements for adult postoperative analgesia.
As the third long-acting analgesic product in Kingpre’s pipeline, the acceptance of QP-6211’s NDA further enriches the company’s product portfolio in the non-opioid analgesic sector and delivers a new solution to unmet clinical pain relief needs.
Yan Peng’an, General Manager of Investment Department III of Nanjing Venture Capital Group, stated:“We warmly congratulate Kingpre Biotech on the official acceptance of the NDA for QP-6211 by CDE. As an innovative benchmark in non-opioid analgesics, this product will bring a breakthrough upgrade over traditional analgesic regimens, effectively avoiding the addiction risk of opioid drugs, and is expected to break the limitations of conventional drugs in China’s postoperative analgesia market. With China-originated formulation technology, it will reshape the competitive landscape of the global long-acting analgesic field.”
“Nanjing Venture Capital Group first invested in Kingpre Biotech in December 2022 through the Sci-Tech Innovation Fund, and provided additional investment in March 2023 via the Municipal Talent Fund Phase II. Through direct investment and collaborative sub-funds, we have witnessed the company’s milestone achievement of simultaneous approvals in China and the US for its first product QP-001, and supported it in building a fully proprietary sustained-release technology platform.”
“The latest progress of QP-6211 will further improve the innovation ecosystem of Nanjing’s biomedical industry chain, attract global talent and technological resources in biomedicine, strengthen Nanjing’s industrial competitiveness in innovative drug R&D, and inject solid impetus into building the city into a highland for new medicine and life health industries.”
Source: Wu Jun, Investment Department III
Reviewed by: Xue Yao
Released by: You Yi
